Search Results - "Castro‐Fernández, Manuel"
-
1
Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease
Published in Journal of gastroenterology and hepatology (01-02-2014)“…Background and Aim To identify predictive factors related to the development of erythema nodosum and pyoderma gangrenosum, in patients with inflammatory bowel…”
Get full text
Journal Article -
2
SYMPTOMATIC HYPOMAGNESEMIA INDUCED BY PROTON-PUMP INHIBITORS (PPIs). A KNOWN ADVERSE EVENT THAT IS WORTH RECALLING
Published in Revista española de enfermedades digestivas (01-10-2021)“…Hypomagnesemia is one of the uncommon adverse effects of drugs as widely used as proton pump inhibitors, which we must know in order to include it in our…”
Get full text
Journal Article -
3
Emergence of Inflammatory Bowel Disease During Treatment With Secukinumab
Published in Journal of Crohn's and colitis (29-08-2018)“…Secukinumab is an anti-IL 17A monoclonal antibody currently licensed for the treatment of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis…”
Get full text
Journal Article -
4
Vedolizumab-induced cholestatic liver injury
Published in Gastroenterología y hepatología (01-01-2022)Get more information
Journal Article -
5
European Registry on Helicobacter pylori management: Single‐capsule bismuth quadruple therapy is effective in real‐world clinical practice
Published in United European gastroenterology journal (01-02-2021)“…Background There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating…”
Get full text
Journal Article -
6
-
7
Helicobacter Pylori First-Line and Rescue Treatments in the Presence of Penicillin Allergy
Published in Digestive diseases and sciences (01-02-2015)“…Background Helicobacter pylori eradication is a challenge in penicillin allergy. Aim To assess the efficacy and safety of first-line and rescue treatments in…”
Get full text
Journal Article -
8
Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice
Published in Journal of gastroenterology and hepatology (01-01-2016)“…Background and Aim: The optimal time to withdraw combined biological + immunosuppressive therapy in Crohn's disease is debated. Following remission of 6 months…”
Get full text
Journal Article -
9
Coexistence of Pyoderma Gangrenosum and Sweet's Syndrome in a Patient With Ulcerative Colitis
Published in The American journal of gastroenterology (01-12-2007)Get full text
Journal Article -
10
Tetany and convulsions: onset symptoms in Crohn's disease
Published in Revista española de enfermedades digestivas (01-12-2014)Get full text
Journal Article -
11
Tetany and convulsions: Onset symptoms in Crohn's disease
Published in Revista española de enfermedades digestivas (01-12-2014)Get full text
Journal Article -
12
Cutaneous lymphoma in a patient with ulcerative colitis after immunosuppressive therapy
Published in Journal of Crohn's and colitis (01-12-2011)“…Biologics are generally safe and well tolerated. However, the risk of haematopoietic cancer in patients with inflammatory bowel disease receiving infliximab…”
Get full text
Journal Article -
13
Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients
Published in Clinical gastroenterology and hepatology (01-01-2020)“…Due to the poor eradication rates of standard triple therapy, the addition of bismuth salts has been proposed for first-line eradication of Helicobacter…”
Get full text
Journal Article -
14
Relationship between H. pylori and hepatitis A virus infection
Published in Revista española de enfermedades digestivas (01-04-2012)Get full text
Journal Article -
15
V Spanish Consensus Conference on Helicobacter pylori infection treatment
Published in Gastroenterología y hepatología (01-05-2022)“…Helicobacter pylori infection is very common in the Spanish population and represents the main cause of chronic gastritis, peptic ulcer, and gastric cancer…”
Get more information
Journal Article -
16
Helicobacter pylori first‐line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp‐EuReg)
Published in Helicobacter (Cambridge, Mass.) (01-06-2020)“…Background Experience in Helicobacter pylori eradication treatment of patients allergic to penicillin is very scarce. A triple combination with a PPI,…”
Get full text
Journal Article -
17
IV Spanish Consensus Conference on Helicobacter pylori infection treatment
Published in Gastroenterología y hepatología (01-12-2016)“…Helicobacter pylori approximately infect 50% of Spanish population and causes chronic gastritis, peptic ulcer and gastric cancer. Until now, three consensus…”
Get more information
Journal Article -
18
Clinical Practice Guidelines. V Spanish Consensus Conference on Helicobacter pylori infection treatment
Published in Revista española de enfermedades digestivas (01-10-2021)“…Helicobacter pylori infection is very common in the Spanish population and represents the main cause of chronic gastritis, peptic ulcer, and gastric cancer…”
Get full text
Journal Article -
19
Recurrence of Helicobacter pylori Infection: 3650 Patient-years Follow-up Study
Published in Helicobacter (Cambridge, Mass.) (01-10-2008)Get full text
Journal Article -
20
Second-line Therapy With Levofloxacin After Failure of Treatment to Eradicate Helicobacter pylori Infection: Time Trends in a Spanish Multicenter Study of 1000 Patients
Published in Journal of clinical gastroenterology (01-02-2013)“…BACKGROUND:Second-line bismuth-containing quadruple therapy is complex and frequently induces adverse effects. A triple rescue regimen containing levofloxacin…”
Get full text
Journal Article